Navigation Links
Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
Date:11/2/2008

Novartis notified of data set closing, Top-line results expected in

November

SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has closed the data set for preliminary analysis of the primary endpoint in the phase III EXTEND (PIX301) trial of pixantrone (BBR2278) for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma (NHL) and it has provided Novartis notice that the data set has been closed. The primary endpoint for the study is the complete remission (CR) and unconfirmed complete remission (uCR) rate in patients receiving either pixantrone or another single agent chemotherapeutic drug. CTI plans to report top-line results in November.

"We are excited to have reached the end of the treatment phase and follow-up period for the pixantrone pivotal study and look forward to reporting top-line results in November," said James A. Bianco, M.D., CEO of Cell Therapeutics. "Complete remissions in this patient population with end stage advanced disease are seldom accomplished with the current standard of care. Pixantrone, if successful in achieving the study objectives, could offer these patients a significant benefit, and we would work with the FDA to submit an NDA in 2009."

CTI has an existing license and co-development agreement with Novartis for OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which also provides Novartis with an option to enter into an exclusive worldwide license to develop and commercialize pixantrone based upon agreed terms.

About the EXTEND (PIX301) Clinical Trial

The EXTEND clinical trial is a phase III single agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial was conducted at 130 sites in 17 countries. Patients were randomized to receive either pixantr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
2. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
3. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
4. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
5. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
6. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
7. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
8. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
9. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
10. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
11. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Tenn. , Dec. 22, 2014   TRU-D ... automated, no-touch UV disinfection robot, announced today that the ... Schedule contract through November 2019.   This ... rapidly engage all levels of government purchasers, including Department ... as well as Homeland Security contacts purchasing solutions for ...
(Date:12/22/2014)... HOUSTON , Dec. 22, 2014 Cyberonics, Inc. ... devices for the treatment and management of epilepsy, today announced ... Morgan Healthcare Conference on Wednesday, January 14, 2015, in ... , Cyberonics, President and Chief Executive Officer, will speak at ... presentation can be accessed by clicking on the Investor Relations ...
(Date:12/22/2014)... , Dec. 22, 2014  Mark Farrah ... brief providing a summary of the 2015 marketplace ... enrollment trends.  According to a ... Planning and Evaluation, Department of Health and Human ... enrolled in individual medical plans through the Marketplace ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2Insights into the Marketplace and Individual Market Growth 2
... Meeting , , ATLANTA, Dec. ... the once-daily antiepileptic drug (AED) Keppra XR(TM) (levetiracetam) extended-release tablets ... additional dosing schedules. The data were among five studies that ... Epilepsy Society (AES) in Seattle. , ...
... Millennium: The Takeda Oncology Company today reported updated ... from the large, international Phase III VISTA(1) trial ... untreated multiple myeloma given VELCADE, melphalan and prednisone ... all patient sub-groups, including those with poor prognostic ...
Cached Medicine Technology:New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 2New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 3New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 4New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 5New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 6Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... June 2011 The Reed Elsevier Environmental Challenge aims ... and sustainable water supply for communities where it is ... $50,000 first prize, announced today, is Tagore-SenGupta Foundation. Their ... in remote villages and schools in Cambodia where arsenic ...
... highlights that while the risk of post-traumatic stress disorder (PTSD) ... migraine irrespective of sex, the risk is greater in male ... Headache: The Journal of Head and Face Pain , ... In this paper, lead author B. Lee Peterlin ...
... range of new "apps" and other technologies harnessing health ... demonstrated at the Health Data Initiative Forum, hosted by ... and Human Services, on Thursday, June 9. IT ... gather at the event hosted by the Institute of ...
... bona fide media presenting official press credentials , Media ... & IT support, English, Swedish, Spanish, German, and French ... is English] News briefings will be held:, ... CEST Monday 4 July (English), 14.00 hrs CEST Monday ...
... to suffer surgical site infections (SSIs) if the operating theatre ... of BJS, the British Journal of Surgery . ... surgery, exploring demographic parameters, the duration of the operation and ... per cent) developed SSIs and the only variable was the ...
... Asian non-small cell lung cancer (NSCLC) patients survive longer than ... first-line setting, and the effect was apparent both before and ... according to research published in the June issue of the ... Asian patients with a common type of lung cancer, the ...
Cached Medicine News:Health News:Reed Elsevier Environmental Challenge winners announced 2Health News:Sex matters -- more men with migraine suffer from PTSD than women 2Health News:Sex matters -- more men with migraine suffer from PTSD than women 3Health News:Health data forum features dynamic apps, experts on June 9 2Health News:European Society of Human Reproduction and Embryology Annual Meeting July 3-6, 2011, Stockholm 2Health News:European Society of Human Reproduction and Embryology Annual Meeting July 3-6, 2011, Stockholm 3Health News:Noisy operations associated with increased infections after surgery 2Health News:Asian lung cancer patient survival exceeds Caucasians' on multiple regimens 2
Electric high speed system....
Compressor-cooled plate used to keep blocks cold while sectioning....
... CO-Oximeter Control (Bayer 800 Series) is ... monitoring the performance of blood gas, ... 270 and 800 series) instrumentation. This ... Bayer 800 Rapidlab Series instruments in ...
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Medicine Products: